바이오의약품 시장 : 제품 유형, 서비스, 원료 유형, 용도별 - 세계 예측(2025-2030년)

The Biopharmaceuticals Market was valued at USD 574.04 billion in 2023, expected to reach USD 627.19 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 1,100.51 billion by 2030.

The biopharmaceutical industry encompasses the research, development, and manufacturing of biological drugs and therapies derived from living organisms. This sector plays a critical role due to its capacity to treat complex diseases like cancer and autoimmune disorders. The necessity of biopharmaceuticals lies in their advanced efficacy and specificity, offering fewer side effects and personalized treatment options compared to traditional pharmaceuticals. Applications include vaccines, monoclonal antibodies, and cell and gene therapies, with end use spanning hospitals, specialty clinics, and research institutes.

Market growth is primarily driven by the increasing prevalence of chronic diseases, technological advancements, and heightened investments in R&D. Additionally, supportive government policies and growing demand for effective therapies create substantial opportunities for industry players. One emerging opportunity lies in the development of biosimilars, which can offer cost-effective alternatives to expensive biopharmaceuticals. Another potential area is leveraging artificial intelligence (AI) and machine learning for drug discovery and personalized medicine, which can reduce time-to-market and enhance treatment efficacy.

Despite robust growth prospects, the biopharma market faces limitations, including high R&D costs, complex manufacturing processes, and stringent regulatory requirements. Challenges like market access barriers and intellectual property issues further hinder growth and adoption. To address these, firms should consider investing in partnerships and collaborations that can accelerate research and streamline production processes, utilize AI to innovate drug development, and explore emerging markets with favorable regulatory scenarios.

Innovative areas for business growth include gene editing technologies like CRISPR, novel drug delivery systems, and expanding vaccine platforms, especially mRNA technology. These advancements promise to revolutionize treatment paradigms and create new revenue streams. The market is characterized by intense competition, rapid technological shifts, and a high degree of specialization, necessitating strategic agility and continuous innovation to maintain leadership and capture emerging opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biopharmaceuticals Market

The Biopharmaceuticals Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of Chronic Diseases and Need for Targeted Biopharmaceuticals
  • Rising Investments in Vaccine and Drugs Development
  • Attractive Reimbursement Policies for Biopharmaceuticals
• Market Restraints
  • Raw Material Supply Chain Disruptions and High Cost of Drug Development
• Market Opportunities
  • Advancements in Biopharmaceutical Manufacturing and Testing Technologies
  • Emerging Trends of Outsourcing Biologics and Vaccine Manufacturing
• Market Challenges
  • Stringent Regulatory Framework for Drug Manufacturing and Time-Consuming Clinical Trials

Porter's Five Forces: A Strategic Tool for Navigating the Biopharmaceuticals Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biopharmaceuticals Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biopharmaceuticals Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biopharmaceuticals Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biopharmaceuticals Market

A detailed market share analysis in the Biopharmaceuticals Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biopharmaceuticals Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biopharmaceuticals Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Avidea Technologies, Bayer AG, Thermo Fisher Scientific Inc., Ferring Pharmaceuticals, Abbott Laboratories, LG Chem Life Sciences Innovation Center, Inc., Ipsen Pharma, Novo Nordisk A/S, Amgen Inc., BTL Biotechno Labs Pvt. Ltd., Johnson & Johnson Services, Inc., Pfizer, Inc., bioMerieux SA, Nordic BioSite, GlaxoSmithKline PLC, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Sanofi S.A., Abgenex, AstraZeneca PLC, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Bio-Techne Corporation, and Biogen Inc..

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Monoclonal Antibodies, Purified Proteins, Recombinant Growth Factors, Recombinant Hormone, Recombinant Proteins, Synthetic Immunomodulators, and Vaccines.
• Based on Services, market is studied across Compendial & Multi Compendial Laboratory Testing, Custom Testing or Customer Proprietary Testing, and Laboratory Testing.
• Based on Raw Material Type, market is studied across Active Pharmaceutical Ingredient and Formulation Excipients.
• Based on Application, market is studied across Autoimmune Disorders, Cardiovascular Diseases, Hormonal Disorders, Immunology, Inflammatory & Infectious Diseases, Metabolic Disorders, Neurological Diseases, and Oncology.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of Chronic Diseases and Need for Targeted Biopharmaceuticals
    • 5.1.1.2. Rising Investments in Vaccine and Drugs Development
    • 5.1.1.3. Attractive Reimbursement Policies for Biopharmaceuticals
  • 5.1.2. Restraints
    • 5.1.2.1. Raw Material Supply Chain Disruptions and High Cost of Drug Development
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in Biopharmaceutical Manufacturing and Testing Technologies
    • 5.1.3.2. Emerging Trends of Outsourcing Biologics and Vaccine Manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Regulatory Framework for Drug Manufacturing and Time-Consuming Clinical Trials
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Ongoing R&D initiatives to promote innovations in the field of monoclonal antibodies
  • 5.2.2. Services: Need for compendial & multi compendial laboratory testing to ensure compliance with regulations
  • 5.2.3. Raw Material Type: Efforts to develop potent APIs to diagnose, cure, or mitigate disease conditions
  • 5.2.4. Application: Changes in lifestyles leading to the need for treatment strategies for cardiovascular diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Biopharmaceuticals Market, by Product Type

• 6.1. Introduction
• 6.2. Monoclonal Antibodies
• 6.3. Purified Proteins
• 6.4. Recombinant Growth Factors
• 6.5. Recombinant Hormone
• 6.6. Recombinant Proteins
• 6.7. Synthetic Immunomodulators
• 6.8. Vaccines

7. Biopharmaceuticals Market, by Services

• 7.1. Introduction
• 7.2. Compendial & Multi Compendial Laboratory Testing
• 7.3. Custom Testing or Customer Proprietary Testing
• 7.4. Laboratory Testing

8. Biopharmaceuticals Market, by Raw Material Type

• 8.1. Introduction
• 8.2. Active Pharmaceutical Ingredient
• 8.3. Formulation Excipients

9. Biopharmaceuticals Market, by Application

• 9.1. Introduction
• 9.2. Autoimmune Disorders
• 9.3. Cardiovascular Diseases
• 9.4. Hormonal Disorders
• 9.5. Immunology
• 9.6. Inflammatory & Infectious Diseases
• 9.7. Metabolic Disorders
• 9.8. Neurological Diseases
• 9.9. Oncology

10. Americas Biopharmaceuticals Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Biopharmaceuticals Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Biopharmaceuticals Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
  • 13.3.2. LEQEMBI Intravenous Infusion (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20
  • 13.3.3. HHS Announces Details of Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies

Companies Mentioned

• 1. AbbVie Inc.
• 2. Avidea Technologies
• 3. Bayer AG
• 4. Thermo Fisher Scientific Inc.
• 5. Ferring Pharmaceuticals
• 6. Abbott Laboratories
• 7. LG Chem Life Sciences Innovation Center, Inc.
• 8. Ipsen Pharma
• 9. Novo Nordisk A/S
• 10. Amgen Inc.
• 11. BTL Biotechno Labs Pvt. Ltd.
• 12. Johnson & Johnson Services, Inc.
• 13. Pfizer, Inc.
• 14. bioMerieux SA
• 15. Nordic BioSite
• 16. GlaxoSmithKline PLC
• 17. Novartis AG
• 18. Eli Lilly and Company
• 19. Merck & Co., Inc.
• 20. Bristol-Myers Squibb Company
• 21. Sanofi S.A.
• 22. Abgenex
• 23. AstraZeneca PLC
• 24. F. Hoffmann-La Roche AG
• 25. Takeda Pharmaceutical Company Limited
• 26. Bio-Techne Corporation
• 27. Biogen Inc.